Nivolumab

Human IgG4 kappa

Immobilized hu-PD-1-His can bind Nivolumab. The EC ₅₀ for this effect is 6.195 ng/mL.

Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Nivolumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells.

Nivolumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2025 May 22;13(5):e011080. [Abstract]

Customer Validation
Nivolumab (25 µg/mL). FCM analysis of effector cytokine expression, including IFN-γ, in CD8⁺T cells across different treatment groups. Histogram overlays depict cytokine expression levels, while bar graphs quantify the percentage of GZMB⁺, IFN-γ⁺, and perforin⁺CD8⁺ T cells.

Nivolumab purchased from MedChemExpress. Usage Cited in: Adv Healthc Mater. 2025 Nov 28.

Customer Validation
Activated Jurkat cells were treated for 2 h with anti PD-1 monoclonal antibody (Nivolumab, 10 µg/mL) and then co-cultured with cancer-on-a-bead model for an additional 24 h in the continued presence of the antibody. T cells apoptosis/necrosis was analyzed with Annexin/PI staining by flow cytometry. The displayed dot plot represents one experiment, typical of three independent experiments conducted.

Nivolumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 22;15(1):2567. [Abstract]

Customer Validation
Representative proliferation assay of co-cultures using patient-derived intratumor NKs and NCI-H23 cells. NK anti-tumor activity was assessed in the presence of BETi (1 µM OTX015) and/or the anti-PD-1 inhibitor Nivolumab (15 µg/mL; 24-72 h) (n = 3 co-cultures from a single patient).

Nivolumab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Aug 13:e177413. [Abstract]

Customer Validation
Survival of low-grade glioma GEMM mice using Kaplan-Meier analysis. IgG: n = 20 mice (median survival [MS]: 110.5 days), anti–PD-1 (Nivolumab, 200 μg/mouse; i.p.; three times per week for 3 weeks): n = 20 mice (MS: 134.5 days), anti-TIM3: n = 21 mice (MS: 253 days). Statistics (log-rank test): control versus anti–PD-1 (Nivolumab), P = 0.64; control versus anti-TIM3, P < 0.01; anti-TIM3 versus anti–PD-1 (Nivolumab), P = 0.02.

Nivolumab purchased from MedChemExpress. Usage Cited in: Mol Ther. 2022 Feb 2;30(2):621-631. [Abstract]

Customer Validation
IFN-γ does not increase in the context of PD-L1^−/P146R relative to PD-L1^−/WT. Co-cultures of T cells and the GC cells with or without Nivolumab (1 ng/μL; 4 days). IFN-γ concentration was measured in the supernatant. The results showed that Nivolumab significantly enhanced IFN-γ secretion from T cells.